The new era of ALL treatment

Safety considerations for inotuzumab in patients with relapsed/refractory ALL

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer

Novel therapeutic approaches in B-progenitor ALL

Professional safety for oncology nurses

Endocrine dysfunction in patients receiving immunotherapy

Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection

Dasatinib vs imatinib in the treatment of paediatric ALL

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients

PET-Directed therapy for early-stage diffuse large B-cell lymphoma

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC